|
||||||||||||||||
| HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
| Antibody Technology Financing and Deal-Making | ||||||||||||||||
| March 04, 2002 | ||||||||||||||||
|
Wyndham Emerald Plaza, San Diego, CA April 8-9, 2002 ORGANIZED INTO THREE SECTIONS: Venture-Backed Antibody & Antibody Mimic Startups Partnering of Early-Stage Antibody Technologies Licensing & Deal-Making: The Bigger Picture KEY INSIGHTS ON: * Buy-Side & VC Perspective of Antibody Investments * Bypassing VC's: Obstacles & Opportunities * Licensing of Early-Stage Antibody Therapeutics * PDL - Exelixis: Novel Transaction Structure * The Biotech-Biotech Alliance - Cambridge Antibody Technology * The Lexicon - Abgenix Collaboration * Mab Partnering - Corixa * Creative Deal Structuring - Celltech Group plc * Maximum Adaptability Partnering Strategy: Medarex - KIRIN |
||||||||||||||||
| Organized by: | Strategic Research Institute | |||||||||||||||
| Invited Speakers: | KEYNOTE PRESENTATION: Wall Street's View on Antibody Financing Fariba F. Ghosian, Ph.D. Managing Director, Healthcare Research Financial Analyst ROTH CAPITAL PARTNERS Tom Redington REDINGTON INC. FEATURING: Abgenix AbTECH S.A. Affitech A.S. Altarex Corporation Amgen Arius Research Atopix Pharmaceuticals Bard Biopharma Bioscience Ventures, Inc. Cambridge Antibody Technology Celltech Group plc Chiron Corporation Corixa Corporation Exelixis Inc. Forward Ventures Genentech Genway Biotech IDEC Pharmaceuticals Immunogen Inc. J.P. Morgan Chase H & Q Johnson & Johnson Lexicon Genetics Medarex Merck & Company Protein Design Labs Raven Biotechnologies Roth Capital Wyeth Ayerst |
|||||||||||||||
| Deadline for Abstracts: | none | |||||||||||||||
| Registration: | www.srinstitute.com/cs206 (212) 967-0095 |
|||||||||||||||
| E-mail: | ckahan-radhuber@srinstitute.com | |||||||||||||||
| Posted by: | Cheryl Kahan-Radhuber | |||||||||||||||
| Host: | 12.3.58.15 | |||||||||||||||
|
||||||||||||||||
|
Generated by meetings and positions 5.0 by Kai Garlipp |
||||||||||||||||